Compliance Rate

Compliance Rate 100.0%
Compliant submissions 1
Incompliant submissions 0
Total trials 1

My Organizations' Clinical Trials

Showing 500 of 2051 entries
View as:

Trial to Assess the Safety and Effects of Vorapaxar in Japanese Subjects With Acute Coronary Syndrome (P04772; MK-5348-016)

Phase: N/A Priority: Normal
NCT ID: NCT00684203 Org: User:
Start: 12/01/06 End: 10/01/07 Due: 10/01/08

A Study to Determine the Activity of Caelyx With Trastuzumab and Docetaxel in the Treatment of Metastatic Breast Cancer (Study P03679)

Phase: N/A Priority: Normal
NCT ID: NCT00687440 Org: User:
Start: 07/15/05 End: 10/24/08 Due: 10/24/09

A Study of MK-2060 in Participants With Chronic and/or End-Stage Kidney Disease (MK-2060-011)

Phase: N/A Priority: Normal
NCT ID: NCT05656040 Org: User:
Start: 02/08/23 End: 08/12/24 Due: 08/12/25

Lot-to-Lot Consistency of V114 in Healthy Adults (V114-020)

Phase: N/A Priority: Normal
NCT ID: NCT03950856 Org: User:
Start: 06/12/19 End: 04/03/20 Due: 04/03/21

A Study of MK0217A and Dietary Supplement in Men and Postmenopausal Women With Osteoporosis (0217A-227)

Phase: N/A Priority: Normal
NCT ID: NCT00092079 Org: User:
Start: 01/31/04 End: 11/30/04 Due: 11/30/05

The Incidence of Extra-Articular Manifestations in Participants With Ankylosing Spondylitis Treated With Golimumab (MK-8259-012)

Phase: N/A Priority: Normal
NCT ID: NCT01668004 Org: User:
Start: 09/03/12 End: 04/30/15 Due: 04/30/16

Efficacy and Safety Study of Fosaprepitant (MK-0517) Plus Ondansetron Versus Ondansetron Alone for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-044)

Phase: N/A Priority: Normal
NCT ID: NCT02519842 Org: User:
Start: 09/14/15 End: 02/24/17 Due: 02/24/18

Imipenem/Relebactam/Cilastatin Versus Piperacillin/Tazobactam for Treatment of Participants With Bacterial Pneumonia (MK-7655A-014)

Phase: N/A Priority: Normal
NCT ID: NCT02493764 Org: User:
Start: 11/24/15 End: 04/03/19 Due: 04/03/20

Efficacy, Safety and Pharmacokinetics of Sugammadex (Org 25969; MK-8616) at 3 Different Time Points After 0.6 mg/kg Esmeron® in Male Participants (P05940; MK-8616-020).

Phase: N/A Priority: Normal
NCT ID: NCT03519854 Org: User:
Start: 12/01/02 End: 06/01/03 Due: 06/01/04

A Study to Evaluate Oral Formulations of Tedizolid Phosphate in Healthy Participants (MK-1986-043)

Phase: N/A Priority: Normal
NCT ID: NCT06733688 Org: User:
Start: 03/23/22 End: 04/15/22 Due: 04/15/23

MK-8189 Multiple Dose Study in Healthy Volunteers and Schizophrenia Participants (MK-8189-003)

Phase: N/A Priority: Normal
NCT ID: NCT02181803 Org: User:
Start: 08/05/14 End: 04/23/15 Due: 04/23/16

A Study to Test the Safety and Efficacy of MK-8998 in Acutely Psychotic Participants With Schizophrenia (MK-8998-004)

Phase: N/A Priority: Normal
NCT ID: NCT00827918 Org: User:
Start: 03/31/09 End: 04/30/10 Due: 04/30/11

A Study of Doravirine (MK-1439) in Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Participants (MK-1439-005)

Phase: N/A Priority: Normal
NCT ID: NCT01466985 Org: User:
Start: 10/21/11 End: 04/10/12 Due: 04/10/13

Study of Epacadostat (INCB024360) Alone and In Combination With Pembrolizumab (MK-3475) With Chemotherapy and Pembrolizumab Without Chemotherapy in Participants With Advanced Solid Tumors (MK-3475-434)

Phase: N/A Priority: Normal
NCT ID: NCT02862457 Org: User:
Start: 08/23/16 End: 11/20/20 Due: 11/20/21

A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010)

Phase: N/A Priority: Normal
NCT ID: NCT05665595 Org: User:
Start: 01/19/23 End: 08/27/25 Due: 08/27/26

Investigation of 9 Consecutive Infusions of Remicade for Psoriatic Arthritis in Austria (Study P04264)

Phase: N/A Priority: Normal
NCT ID: NCT00725296 Org: User:
Start: 12/31/04 End: 07/31/10 Due: 07/31/11

An Investigational Drug Study in Patients With Type 2 Diabetes Mellitus (MK0431-023)

Phase: N/A Priority: Normal
NCT ID: NCT00094757 Org: User:
Start: 10/06/04 End: 04/28/06 Due: 04/28/07

A Study of Rofecoxib in Familial Adenomatous Polyposis (FAP) (0966-205)(TERMINATED)

Phase: N/A Priority: Normal
NCT ID: NCT00140894 Org: User:
Start: 08/06/02 End: 10/11/04 Due: 10/11/05

Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015)

Phase: N/A Priority: Normal
NCT ID: NCT04662710 Org: User:
Start: 12/30/20 End: 03/31/26 Due: 03/31/27

Safety, Tolerability and Pharmacokinetics of MK-0873 Following Patch Application in Healthy Participants and Psoriasis Participants (MK-0873-020)

Phase: N/A Priority: Normal
NCT ID: NCT01140061 Org: User:
Start: 05/01/10 End: 03/01/11 Due: 03/01/12

Safety and Effectiveness of Giving Indinavir, Ritonavir, Stavudine, and Lamivudine to HIV-Infected Patients Who Have Never Received Anti-HIV Drugs

Phase: N/A Priority: Normal
NCT ID: NCT00002451 Org: User:
Start: - End: - Due: -

A Study to Evaluate Efficacy and Safety of Four Posaconazole Regimens With Placebo and Terbinafine in the Treatment of Toenail Onychomycosis (Study P05082AM2)(COMPLETED)

Phase: N/A Priority: Normal
NCT ID: NCT00491764 Org: User:
Start: 06/30/07 End: 12/31/08 Due: 12/31/09

A Study to Evaluate MK1903 in Patients With Dyslipidemia (MK1903-004)

Phase: N/A Priority: Normal
NCT ID: NCT00847197 Org: User:
Start: 06/30/08 End: 09/30/09 Due: 09/30/10

Double-blind Sitagliptin Add-on Study in Japanese Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Ipragliflozin (MK-0431J-842)

Phase: N/A Priority: Normal
NCT ID: NCT02577016 Org: User:
Start: 11/05/15 End: 11/18/16 Due: 11/18/17

The Effect of Antacids on the Pharmacokinetics (PK) of Raltegravir in Human Immunodeficiency Virus (HIV)-Infected Participants (MK-0518-824)

Phase: N/A Priority: Normal
NCT ID: NCT02473367 Org: User:
Start: 06/23/15 End: 10/09/15 Due: 10/09/16